Finance

Lists
Why is ALNOV down 3,64%?
Dive Deeper
ALNOV:EPA
Novacyt SA
0,41 €
-3,64%
(-0,016) 1D
5 ნოე, 17:35:20 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
0,42 €
High
0,43 €
Low
0,41 €
Mkt. cap
29,49 მლნ.
Avg. vol.
198,56 ათ.
Volume
133,90 ათ.
52-wk high
1,04 €
52-wk low
0,29 €
EPS
-0,38 €
Shares outstanding
72,59 მლნ.
No. of employees
228
Open
0,42 €
High
0,43 €
Low
0,41 €
Mkt. cap
29,49 მლნ.
Avg. vol.
198,56 ათ.
Volume
133,90 ათ.
52-wk high
1,04 €
52-wk low
0,29 €
EPS
-0,38 €
Shares outstanding
72,59 მლნ.
No. of employees
228
News stories
From web sources and news partners
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEOდავიდ ალმონდ
Employees228
Founded3 ივლ. 2006
Headquarters-
SectorHealth Care
Industry-
Websitenovacyt.com
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
5,12 მლნ.
5,12 მლნ.
5,78 მლნ.
5,78 მლნ.
Cost of goods sold
2,61 მლნ.
2,61 მლნ.
2,56 მლნ.
2,56 მლნ.
Cost of revenue
2,61 მლნ.
2,61 მლნ.
2,56 მლნ.
2,56 მლნ.
Research and development expenses
1,03 მლნ.
1,03 მლნ.
1,06 მლნ.
1,06 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,69 მლნ.
4,69 მლნ.
4,65 მლნ.
4,65 მლნ.
Operating expense
5,54 მლნ.
5,54 მლნ.
5,66 მლნ.
5,66 მლნ.
Total operating expenses
8,16 მლნ.
8,16 მლნ.
8,22 მლნ.
8,22 მლნ.
Operating income
-3,04 მლნ.
-3,04 მლნ.
-2,44 მლნ.
-2,44 მლნ.
Other non operating income
-23,00 ათ.
-23,00 ათ.
-47,50 ათ.
-47,50 ათ.
EBT including unusual items
-10,16 მლნ.
-10,16 მლნ.
-2,91 მლნ.
-2,91 მლნ.
EBT excluding unusual items
-2,52 მლნ.
-2,52 მლნ.
-2,80 მლნ.
-2,80 მლნ.
Income tax expense
-1,81 მლნ.
-1,81 მლნ.
-49,50 ათ.
-49,50 ათ.
Effective tax rate
17,85%
17,85%
1,70%
1,70%
Other operating expenses
-180,50 ათ.
-180,50 ათ.
-44,00 ათ.
-44,00 ათ.
Net income
-8,27 მლნ.
-8,27 მლნ.
-2,90 მლნ.
-2,90 მლნ.
Net profit margin
-161,60%
-161,60%
-50,13%
-50,13%
Earnings per share
-
-
-
-
Interest and investment income
149,00 ათ.
149,00 ათ.
63,00 ათ.
63,00 ათ.
Interest expense
-146,00 ათ.
-146,00 ათ.
-139,00 ათ.
-139,00 ათ.
Net interest expenses
3,00 ათ.
3,00 ათ.
-76,00 ათ.
-76,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
3,46 მლნ.
3,46 მლნ.
-1,88 მლნ.
-1,88 მლნ.
Gain or loss from assets sale
-3,00 ათ.
-3,00 ათ.
8,00 ათ.
8,00 ათ.
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები